By 2017, the U.S. infusion therapy device market is expected to reach over $6.6 billion. Growth in this market will be driven by the increased use of antimicrobial mechanical valve needleless connectors for the reduction of catheter-related bloodstream infections (CRBSIs).  Medicare and major insurance companies are no longer reimbursing for vascular access associated infections and facilities must absorb the cost of treating such patients. As a result, hospitals are now purchasing premium-priced antimicrobial needleless connectors making this segment the fastest growing in the market with almost 70% growth in 2010.

iData’s report on “The U.S. Market for Infusion Therapy Devices 2011” includes the latest data, market-analyses and competitor profiles for over 17 segments.

Read more in iData’s newest press release: